Translating Geroscience Into Clinical Practice: Molecular Targets, Emerging Therapies, and Lifestyle Strategies for Healthy Longevity - Cureus

IntroductionProstate cancer is the most common malignancy in men that accounts for 10% of male cancer-related deaths and is expected to increase in incidence in the coming decades1. Its clinical trajectory is highly variable, with disease courses ranging from localised disease with long indolent phases that often require no therapy, to early-onset cancer that typically necessitates definitive treatment with curative intent2 and life-threatening metastatic prostate cancer3. The management of newly diagnosed prostate cancer is primarily based on established clinical and pathological information along with small gene or mRNA panels. The most pressing unmet clinical needs include reliable prognostic approaches to minimize overtreatment and the identification of therapeutic targets4. This is especially challenging due to the considerable molecular heterogeneity of the disease. Its genomic landscape is dominated by structural variation (SV) and copy-number alteration (CNA) drivers, while in contrast, drivers involving small mutations including single-nucleotide variants (SNVs) and insertions-deletions (indels) are relatively infrequent5,6.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.